Regulatory Compliance Management

The “Regulatory Compliance Management” category at AssurX is dedicated to helping organizations navigate the complex landscape of regulatory requirements. This section provides practical tools and expert insights to ensure adherence to industry standards and regulations. It covers a range of topics, including compliance strategy development, risk assessment, and the integration of compliance management systems. By exploring these resources, professionals can streamline their compliance processes and mitigate risks effectively. AssurX equips you with the knowledge and solutions needed to maintain compliance and drive operational excellence.

FDA Guidance on How to Address Inaccurate Online Claims Against Medical Device or Drug Manufacturers
FDA Guidance on How to Address Inaccurate Online Claims Against Medical Device or Drug Manufacturers

FDA Guidance on How to Address Inaccurate Online Claims Against Medical Device or Drug Manufacturers

AssurX Blog2014-06-24T10:11:44+00:00June 24th, 2014|

Distilling the FDA Guidance on How to Address Inaccurate Online Claims Against M [...]

FDA Acts to Harmonize Global Adverse Event Reporting
FDA Acts to Harmonize Global Adverse Event Reporting

Regulatory Compliance Management

Cybersecurity & Reliability Assurance Initiatives Top Priority at NERC Board Meetings

FDA Guidance Advises Device Makers to Think About Home-Use

FDA Spreads Regulatory Love Nationwide

Time to Take a Closer Look at FDA MDDS Moves

FDA Lets MDDS Off The Regulatory Hook

Unprecedented Energy Demand on Aging Grid: Important Discussions at NYISO Energy Conference

FDA Guidance on How to Address Inaccurate Online Claims Against Medical Device or Drug Manufacturers

FDA Guidance on How to Address Inaccurate Online Claims Against Medical Device or Drug Manufacturers

FDA Acts to Harmonize Global Adverse Event Reporting

FDA Acts to Harmonize Global Adverse Event Reporting

Medical Device Warning Letter Round-Up: FDA Won’t Take No For an Answer

Medical Device Industry Endures Tough 2013; 2014 Prospects Not Much Better